These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27283290)

  • 41. [Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer].
    Courtier B; Hadoux J
    Bull Cancer; 2021 Nov; 108(11):989-991. PubMed ID: 34598787
    [No Abstract]   [Full Text] [Related]  

  • 42. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
    Hong D; Ye L; Gagel R; Chintala L; El Naggar AK; Wright J; Kurzrock R
    Mol Cancer Ther; 2008 May; 7(5):1001-6. PubMed ID: 18445656
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synchronous metastatic medullary and papillary thyroid carcinomas in a patient with germline RET mutation: case report, molecular analysis, and implications for pathogenesis.
    Griffith C; Zhang S; Mukhopadhyay S
    Endocr Pathol; 2010 Jun; 21(2):115-9. PubMed ID: 20369307
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modifying impact of
    Kaczmarek-Ryś M; Ziemnicka K; Pławski A; Budny B; Michalak M; Hryhorowicz S; Hoppe-Gołębiewska J; Boruń P; Gołąb M; Czetwertyńska M; Sromek M; Szalata M; Ruchała M; Słomski R
    Endocr Relat Cancer; 2018 Apr; 25(4):421-436. PubMed ID: 29386230
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
    Dadu R; Hu MN; Grubbs EG; Gagel RF
    Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.
    Simbolo M; Mian C; Barollo S; Fassan M; Mafficini A; Neves D; Scardoni M; Pennelli G; Rugge M; Pelizzo MR; Cavedon E; Fugazzola L; Scarpa A
    Virchows Arch; 2014 Jul; 465(1):73-8. PubMed ID: 24828033
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.
    Romei C; Elisei R; Pinchera A; Ceccherini I; Molinaro E; Mancusi F; Martino E; Romeo G; Pacini F
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1619-22. PubMed ID: 8636377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
    Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
    Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting RET receptor tyrosine kinase activation in cancer.
    Phay JE; Shah MH
    Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New multiple somatic mutations in the RET proto-oncogene associated with a sporadic medullary thyroid carcinoma.
    Dvoráková S; Václavíková E; Sýkorová V; Dusková J; Vlcek P; Ryska A; Novák Z; Bendlová B
    Thyroid; 2006 Mar; 16(3):311-6. PubMed ID: 16571096
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array.
    Broutin S; Commo F; De Koning L; Marty-Prouvost B; Lacroix L; Talbot M; Caillou B; Dubois T; Ryan AJ; Dupuy C; Schlumberger M; Bidart JM
    Thyroid; 2014 Jan; 24(1):43-51. PubMed ID: 24256343
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medullary thyroid carcinoma: pitfalls in diagnosis by fine needle aspiration cytology and relationship of cytomorphology to RET proto-oncogene mutations.
    Chang TC; Wu SL; Hsiao YL
    Acta Cytol; 2005; 49(5):477-82. PubMed ID: 16334022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medullary Thyroid Carcinoma Associated with Germline RET
    Xu JY; Grubbs EG; Waguespack SG; Jimenez C; Gagel RF; Sosa JA; Sellin RV; Dadu R; Hu MI; Trotter CS; Jackson M; Rich TA; Hyde SM; Sherman SI; Cote GJ
    Thyroid; 2016 Dec; 26(12):1744-1751. PubMed ID: 27673361
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 57. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
    Albarel F; Conte-Devolx B; Oliver C
    Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
    Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
    Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.
    Siqueira DR; Romitti M; da Rocha AP; Ceolin L; Meotti C; Estivalet A; Puñales MK; Maia AL
    Endocr Relat Cancer; 2010 Dec; 17(4):953-63. PubMed ID: 20801952
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Significance of the RET proto-oncogene polymorphisms in Turkish sporadic medullary thyroid carcinoma patients.
    Gursoy A; Erdogan MF; Erdogan G
    J Endocrinol Invest; 2006 Nov; 29(10):858-62. PubMed ID: 17185892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.